drugset / Trial / NCT00003026

Hormone Therapy in Treating Patients With Advanced Prostate Cancer

NCT00003026 ↗

RandomizedTreatment

Summary

RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using triptorelin may fight prostate cancer by reducing the production of androgens. PURPOSE: Randomized phase III trial to compare the effectiveness of long-term hormone therapy and triptorelin with no further treatment in treating patients who have advanced prostate cancer previously treated with radiation therapy and 6 months of androgen suppression.

Timeline

Start
1997-04
Primary completion
2001-09
Completion
—

Outcome

Missed primary endpoint

paper the observed hazard ratio was 1.42 (upper 95.71% confidence limit, 1.79; P=0.65 for noninferiority). PMID 19516032 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Bicalutamide Other / unclassified — —
Subject Flutamide Small molecule — —
Subject Triptorelin Other / unclassified — —

Indications